# US 2009/0270702 A1 · Method and apparatus for measuring cancerous changes from reflectance spectral measurements obtained during endoscopic imaging

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270702 A1
- Document ID: US20090270702A1
- Status: Published application
- Kind: A1
- Application number: 11/722,822
- Filed: 2006-01-20
- Published: 2009-10-29
- Earliest claimed: 2005-01-21
- Inventors: Haishan Zeng; Yasser Sherif Fawzy
- Web page: https://patentgrep.com/patent/US20090270702A1

## CPC

- G01N 21/474: {Details of optical heads therefor, e.g. using optical fibres}
- A61B 5/0075: {by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy (A61B5/0071 takes precedence)}
- A61B 5/0084: {for introduction into the body, e.g. by catheters (A61B5/1459 takes precedence)}
- A61B 5/14542: {for measuring blood gases (A61B5/14551 takes precedence)}
- A61B 5/1459: invasive, e.g. introduced into the body by a catheter
- G01J 3/02: Details
- G01J 3/0243: {having a through-hole enabling the optical element to fulfil an additional optical function, e.g. a mirror or grating having a throughhole for a light collecting or light injecting optical fiber}
- G01J 3/0291: {Housings; Spectrometer accessories; Spatial arrangement of elements, e.g. folded path arrangements}
- G01N 21/4795: {spatially resolved investigating of object in scattering medium (in vivo A61B)}
- A61B 1/043: {for fluorescence imaging}
- A61B 1/2676: {Bronchoscopes}
- A61B 5/0066: {Optical coherence imaging}
- A61B 5/0071: {by measuring fluorescence emission}
- A61B 5/0261: {using optical means, e.g. infrared light}
- G01N 21/359: using near infrared light
- G01N 2021/4742: {comprising optical fibres}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G01J: MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY (light sources F21, H01J, H01K, H05B; investigating properties of materials by optical means G01N)

## Abstract

The present invention provides a new method and device for disease detection, more particularly cancer detection, from the analysis of diffuse reflectance spectra measured in vivo during endoscopic imaging. The measured diffuse reflectance spectra are analyzed using a specially developed light-transport model and numerical method to derive quantitative parameters related to tissue physiology and morphology. The method also corrects the effects of the specular reflection and the varying distance between endoscope tip and tissue surface on the clinical reflectance measurements. The model allows us to obtain the absorption coefficient (μa) and further to derive the tissue micro-vascular blood volume fraction and the tissue blood oxygen saturation parameters. It also allows us to obtain the scattering coefficients (μs and g) and further to derive the tissue micro-particles volume fraction and size distribution parameters.

## Claims

### Claim 1

A method of obtaining information about tissue physiology and morphology from diffuse reflectance spectra, comprising:
illuminating a tissue with a broadbeam radiation to produce returning radiation;
measuring a reflectance spectra of said returning radiation with a non-contact probe;
determining a diffuse reflectance spectra from said measured reflectance spectra;
analyzing said diffuse reflectance spectra by one-dimensional light transportation modelling;
extracting at least one optical property of the tissue from said analyzed diffuse reflectance spectra; and
deriving information about at least one of a physiology and a morphology of the tissue from said at least one optical property.

### Claim 2 (depends on 1)

The method of claim 1, wherein said at least one optical property comprises at least one of an optical absorption coefficient, a scattering coefficient, and a scattering anisotropy.

### Claim 3 (depends on 1)

The method of claim 1, wherein said one-dimensional light transportation modelling comprises a forward model, an absorption model, a scattering model, and an inversion algorithm.

### Claim 4 (depends on 3)

The method of claim 3, wherein said forward model is used to model a system having known optical properties to calculate a computed value of said diffuse reflectance spectra.

### Claim 5 (depends on 4)

The method of claim 4, wherein said known optical properties are at least one of an optical absorption coefficient, a scattering coefficient, and a scattering anisotropy.

### Claim 6 (depends on 3)

The method of claim 3, wherein said absorption model expresses an absorption coefficient in terms of blood contents and in vitro tissue optical parameters.

### Claim 7 (depends on 6)

The method of claim 6, wherein said absorption coefficient is at least one of an oxygen saturation and a blood volume fraction.

### Claim 8 (depends on 3)

The method of claim 3, wherein said scattering model expresses a scattering coefficient and a scattering anisotropy in terms of a scattering volume fraction and a size distribution parameter.

### Claim 9 (depends on 8)

The method of claim 8, wherein said scattering coefficient is at least one of a mucosa layer scattering volume fraction and a mucosa layer size-distribution parameter.

### Claim 10 (depends on 3)

The method of claim 3, wherein said inversion algorithm derives tissue physiological and morphological properties from said diffuse reflectance spectra.

### Claim 11 (depends on 10)

The method of claim 10, wherein said tissue physiological and morphological properties are at least one of an oxygen saturation, a blood volume fraction, a mucosa layer scattering volume fraction and a mucosa layer size-distribution parameter.

### Claim 12 (depends on 3)

The method of claim 3, wherein said inversion algorithm further derives values of geometry correction parameters.

### Claim 13 (depends on 12)

The method of claim 12, wherein said geometry correction parameters are used to determine said diffuse reflectance spectra from said measured reflectance spectra.

### Claim 14 (depends on 12)

The method of claim 12, wherein said geometry correction parameters account a specular reflectance collected by said non-contact probe and a variable collection efficiency of said non-contact probe.

### Claim 15 (depends on 1)

The method of claim 1, further comprising classifying the tissue as one of benign and malignant based on said optical property.

### Claim 16 (depends on 15)

The method of claim 15, wherein said classifying step further comprises comparing said at least one optical property to a data set of known pathology.

### Claim 17 (depends on 16)

The method of claim 16, wherein said comparing step comprises using statistical analysis.

### Claim 18 (depends on 1)

The method of claim 1, further comprising at least one other modality for at least one of imaging and spectroscopy.

### Claim 19 (depends on 18)

The method of claim 18, wherein said at least one other modality is chosen from the group consisting of fluorescence imaging, fluorescence spectroscopy, optical coherence tomography, Raman spectroscopy, confocal microscopy, or white-light reflectance imaging.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

An apparatus for obtaining information about tissue physiology and morphology from diffuse reflectance spectra, comprising:
means for illuminating a tissue with a broadbeam radiation to produce returning radiation;
a non-contact probe to measure said returning radiation;
means for measuring a reflectance spectra of said returning radiation;
means for determining a diffuse reflectance spectra from said measured reflectance spectra;
means for analyzing said diffuse reflectance spectra for a two-layer tissue model by one-dimensional light transportation modelling;
means for extracting at least one optical property of the tissue from said analyzed diffuse reflectance spectra; and
means for deriving information about at least one of a physiology and a morphology of the tissue from said at least one optical property.

### Claim 23 (depends on 22)

The apparatus of claim 22, wherein said at least one optical property comprises at least one of an optical absorption coefficient, a scattering coefficient, and a scattering anisotropy.

### Claim 24 (depends on 22)

The apparatus of claim 22, wherein said one-dimensional light transportation modelling comprises a forward model, an absorption model, a scattering model, and an inversion algorithm.

### Claim 25 (depends on 24)

The apparatus of claim 24, wherein said forward model is used to model a system having known optical properties to calculate a computed value of said diffuse reflectance spectra.

### Claim 26 (depends on 25)

The apparatus of claim 25, wherein said known optical properties are at least one of an optical absorption coefficient, a scattering coefficient, and a scattering anisotropy.

### Claim 27 (depends on 24)

The apparatus of claim 24, wherein said absorption model expresses an absorption coefficient in terms of blood contents and in vitro tissue optical properties.

### Claim 28 (depends on 27)

The apparatus of claim 27, wherein said absorption coefficient is at least one of an oxygen saturation and a blood volume fraction.

### Claim 29 (depends on 24)

The apparatus of claim 24, wherein said scattering model expresses a scattering coefficient and a scattering anisotropy in terms of a scattering volume fraction and a size distribution parameter.

### Claim 30 (depends on 29)

The apparatus of claim 29, wherein said scattering coefficient is at least one of a mucosa layer scattering volume fraction and a mucosa layer size-distribution parameter.

### Claim 31 (depends on 24)

The apparatus of claim 24, wherein said inversion algorithm derives tissue physiological and morphological properties from said diffuse reflectance spectra.

### Claim 32 (depends on 31)

The apparatus of claim 31, wherein said tissue physiological and morphological properties are at least one of an oxygen saturation, a blood volume fraction, a mucosa layer scattering volume fraction and a mucosa layer size-distribution parameter.

### Claim 33 (depends on 24)

The apparatus of claim 24, wherein said inversion algorithm further derives values of geometry correction parameters.

### Claim 34 (depends on 33)

The apparatus of claim 33, wherein said geometry correction parameters are used to determine said diffuse reflectance spectra from said measured reflectance spectra.

### Claim 35 (depends on 33)

The apparatus of claim 33, wherein said geometry correction parameters account a specular reflectance collected by said non-contact probe and a variable collection efficiency of said non-contact probe.

### Claim 36 (depends on 22)

The apparatus of claim 22, further comprising means for classifying the tissue as one of benign and malignant based on said tissue optical property.

### Claim 37 (depends on 36)

The apparatus of claim 36, wherein said classifying step further comprises comparing said at least one optical property to a data set of known pathology.

### Claim 38 (depends on 37)

The apparatus of claim 37, wherein said comparing step comprises using statistical analysis.

### Claim 39 (depends on 22)

The apparatus of claim 22, further comprising means for at least one other modality for at least one of imaging and spectroscopy.

### Claim 40 (depends on 39)

The apparatus of claim 39, wherein said at least one other modality is chosen from the group consisting of fluorescence imaging, fluorescence spectroscopy, optical coherence tomography, Raman spectroscopy, confocal microscopy, or white-light reflectance imaging.

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

A system for measuring quantitative information related to cancerous changes in a tissue, comprising:
a non-contact probe;
a light source producing a broadbeam interrogating radiation to illuminate a tissue and to produce returning radiation;
a detecting system coupled to capture said returning radiation; and
a processing unit coupled to said detecting system, said processing unit measuring
a reflectance spectra of said returning radiation, determining a diffuse reflectance spectra of said measured reflectance spectra and classifying the tissue as one of benign and malignant based on said diffuse reflectance spectra.

### Claim 44 (depends on 43)

The apparatus of claim 43 wherein said processing unit further measures at least one optical property of the tissue derived from said diffuse reflectance spectra.

### Claim 45 (depends on 44)

The apparatus of claim 44, wherein said at least one optical property comprises at least one of an optical absorption coefficient and a scattering coefficient.

### Claim 46 (depends on 45)

The apparatus of claim 45, wherein said at least one optical property comprises at least one of a blood volume fraction, an oxygenation saturation parameter, a mucosa layer scattering volume fraction, and a mucosa layer size-distribution parameter.

### Claim 47 (depends on 43)

The apparatus of claim 43, wherein said processing unit models a computed diffuse reflectance spectra for known optical properties using a forward model.

### Claim 48 (depends on 43)

The apparatus of claim 43, wherein said processing unit extracts said at least one optical property of tissue from said diffuse reflectance spectra using an inversion algorithm.

### Claim 49 (depends on 48)

The apparatus of claim 48, wherein said inversion algorithm further derives values of geometry correction parameters.

### Claim 50 (depends on 49)

The apparatus of claim 49, wherein said geometry correction parameters are used to determine said diffuse reflectance spectra from said measured reflectance spectra.

### Claim 51 (depends on 49)

The apparatus of claim 49, wherein said geometry correction parameters account a specular reflectance collected by said non-contact probe and a variable collection efficiency of said non-contact probe.

### Claim 52 (depends on 43)

The apparatus of claim 43, wherein said processing unit further comprises means for comparing said at least one optical property to a data set of known pathology.

### Claim 53 (depends on 52)

The method of claim 52, wherein said means for comparing step uses statistical analysis.

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62 (depends on 43)

The apparatus of claim 43, wherein said detecting system comprises at least a spectrometer.

### Claim 63 (depends on 43)

The apparatus of claim 43, wherein said detecting system comprises an image capture device and a spectrometer.

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66 (depends on 43)

The apparatus of claim 43, further comprising means for at least one other modality for at least one of imaging and spectroscopy.

### Claim 67 (depends on 66)

The apparatus of claim 66, wherein said means for at least one other modality is chosen from the group consisting of fluorescence imaging, fluorescence spectroscopy, optical coherence tomography, Raman spectroscopy, confocal microscopy, or white-light reflectance imaging.

### Claim 68

(canceled)

### Claim 69

(canceled)
